Association of KIR3DL1/S1 and HLA-Bw4 with CD4 T cell counts in HIV-infected Mexican mestizos.

Daniel Hernández-Ramírez, Mario A Esparza-Pérez, José L Ramirez-Garcialuna, J Rafael Arguello, Peter B Mandeville, Daniel E Noyola, Christian A García-Sepúlveda
Author Information
  1. Daniel Hernández-Ramírez: Laboratorio de Genómica Viral y Humana, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, Ave. Venustiano Carranza #2405, Col. Filtros Las Lomas, 78210, San Luis Potosí, SLP, Mexico.

Abstract

Certain genotypic combinations of killer-cell immunoglobulin-like receptors (KIR) and human leukocyte antigens (HLA) have been associated with favourable outcomes after exposure to human immunodeficiency virus in Caucasoid and African populations. Human immunodeficiency virus (HIV) infection is characterized by a rapid exhaustion of CD4 cells, which results in impaired cellular immunity. During this early phase of infection, it is thought that the natural killer (NK) cells represent the main effector arm of the host immune response to HIV. This study investigates whether KIR and HLA factors are associated to CD4 T cell numbers after HIV infection in Mexican mestizos as assessed at the time of initial medical evaluation and subsequent clinical follow-up. KIR and HLA-B gene carrier frequency differences were compared between groups of patients stratified by CD4 T cell numbers as assessed during their first medical evaluation (a point in time at which all patients were anti-retroviral therapy naïve). In addition, the influence that these genetic factors have on averaged historical CD4 cell counts in patients subjected to follow-up (mostly therapy-experienced) was also evaluated. Our results suggest a protective role for the HLA-Bw4 and KIR3D + Bw4 combination in both therapy-naïve and therapy-experienced patients. This report furthers our understanding on the way that immune genes modulate HIV disease progression in less-studied human populations such as the Mexican mestizos with a special focus on CD4 T cell number and behaviour.

References

  1. Immunogenetics. 2005 Sep;57(8):549-58 [PMID: 16086172]
  2. PLoS Pathog. 2007 Apr;3(4):e43 [PMID: 17447840]
  3. Neurology. 2000 Dec 26;55(12):1897-900 [PMID: 11134391]
  4. Methods Mol Biol. 2008;415:49-64 [PMID: 18370147]
  5. Front Immunol. 2012 Aug 20;3:258 [PMID: 22934097]
  6. Eur J Immunol. 1997 Dec;27(12):3095-9 [PMID: 9464792]
  7. Nature. 2010 May 20;465(7296):350-4 [PMID: 20445539]
  8. PLoS One. 2013 Sep 23;8(9):e74442 [PMID: 24086347]
  9. AIDS Res Hum Retroviruses. 2007 Mar;23(3):451-5 [PMID: 17411378]
  10. Nat Rev Immunol. 2005 Mar;5(3):201-14 [PMID: 15719024]
  11. MMWR Recomm Rep. 2008 Dec 5;57(RR-10):1-12 [PMID: 19052530]
  12. Science. 1999 Mar 12;283(5408):1748-52 [PMID: 10073943]
  13. Science. 2013 Apr 5;340(6128):87-91 [PMID: 23559252]
  14. Science. 2003 Apr 11;300(5617):337-9 [PMID: 12690201]
  15. AIDS. 1993 Apr;7(4):497-500 [PMID: 8507416]
  16. Nat Rev Immunol. 2006 Jul;6(7):520-31 [PMID: 16799471]
  17. Nucleic Acids Res. 2011 Jan;39(Database issue):D913-9 [PMID: 21062830]
  18. Immunol Rev. 1997 Feb;155:205-21 [PMID: 9059896]
  19. Nature. 2005 Apr 28;434(7037):1093-7 [PMID: 15793563]
  20. Eur J Immunol. 1975 Feb;5(2):112-7 [PMID: 1234049]
  21. Nat Genet. 2002 Aug;31(4):429-34 [PMID: 12134147]
  22. PLoS Med. 2006 Oct;3(10):e403 [PMID: 17076553]
  23. J Immunol. 2007 Sep 1;179(5):3362-70 [PMID: 17709553]
  24. Tissue Antigens. 2003 Jul;62(1):79-86 [PMID: 12859599]
  25. Trends Microbiol. 2008 Dec;16(12):620-7 [PMID: 18976921]
  26. J Exp Med. 2007 Nov 26;204(12):3027-36 [PMID: 18025129]
  27. AIDS. 2008 Mar 12;22(5):595-9 [PMID: 18317000]
  28. Nature. 2002 May 2;417(6884):95-8 [PMID: 11986671]
  29. BMC Infect Dis. 2013 Sep 02;13:405 [PMID: 24059286]
  30. Tissue Antigens. 1995 Nov;46(5):355-67 [PMID: 8838344]
  31. J Immunol. 2007 Jan 15;178(2):647-51 [PMID: 17202323]
  32. Nucleic Acids Res. 2013 Jan;41(Database issue):D1222-7 [PMID: 23080122]
  33. Nat Genet. 2007 Jun;39(6):733-40 [PMID: 17496894]
  34. Immunol Rev. 2013 Jul;254(1):245-64 [PMID: 23772624]
  35. Immunol Rev. 2001 Jun;181:20-38 [PMID: 11513141]
  36. J Exp Med. 2009 Oct 26;206(11):2557-72 [PMID: 19858347]
  37. MMWR Morb Mortal Wkly Rep. 2014 Oct 10;63(40):886-90 [PMID: 25299604]
  38. J Immunol. 1997 Jun 1;158(11):5237-41 [PMID: 9164941]
  39. J Immunol. 2006 Nov 15;177(10 ):6588-92 [PMID: 17082569]
  40. Eur J Immunol. 1975 Feb;5(2):117-21 [PMID: 1086218]
  41. Immunogenetics. 2002 Nov;54(8):543-50 [PMID: 12439616]
  42. Immunol Invest. 2010 Jan;39(3):268-83 [PMID: 20380523]
  43. PLoS One. 2010 Dec 29;5(12):e15115 [PMID: 21206914]
  44. PLoS One. 2011 Feb 14;6(2):e17043 [PMID: 21347267]
  45. Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [PMID: 11682119]
  46. Adv Immunol. 1989;47:187-376 [PMID: 2683611]
  47. J Immunol. 1996 May 1;156(9):3098-101 [PMID: 8617928]
  48. J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S64-8 [PMID: 21406989]
  49. Curr Opin Immunol. 2005 Oct;17(5):510-6 [PMID: 16084708]
  50. Nat Med. 2006 Dec;12(12):1365-71 [PMID: 17115046]
  51. Int Rev Immunol. 2001 Jun;20(3-4):333-70 [PMID: 11878509]
  52. Mol Biol Rep. 2010 Apr;37(4):1883-90 [PMID: 19609718]
  53. J Immunol. 2002 Dec 1;169(11):6376-85 [PMID: 12444145]
  54. AIDS. 2003 Dec 5;17(18):2581-91 [PMID: 14685052]
  55. Tissue Antigens. 2007 Apr;69 Suppl 1:125-9 [PMID: 17445185]
  56. Nat Med. 2005 Dec;11(12):1290-2 [PMID: 16288280]
  57. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5140-5 [PMID: 11309482]
  58. AIDS. 2005 May;19 Suppl 2:S31-7 [PMID: 15930839]
  59. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9 [PMID: 16141329]
  60. Nucleic Acids Res. 2005 Jan 1;33(Database issue):D523-6 [PMID: 15608253]
  61. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 [PMID: 10694578]
  62. J Immunol. 2008 Mar 15;180(6):3969-79 [PMID: 18322206]
  63. J Immunol. 2005 Jan 1;174(1):36-40 [PMID: 15611225]
  64. J Virol. 2004 Aug;78(16):8844-51 [PMID: 15280492]
  65. J Immunol. 2009 Jun 1;182(11):6727-35 [PMID: 19454667]
  66. PLoS Pathog. 2006 Aug;2(8):e79 [PMID: 16933987]
  67. J Immunol. 2008 Nov 1;181(9):6293-300 [PMID: 18941220]
  68. Tissue Antigens. 2008 Feb;71(2):105-13 [PMID: 18069936]
  69. Annu Rev Immunol. 2011;29:295-317 [PMID: 21219175]
  70. Nature. 2004 Dec 9;432(7018):769-75 [PMID: 15592417]
  71. Immunogenetics. 2011 Sep;63(9):561-75 [PMID: 21638211]
  72. Nat Med. 1996 Apr;2(4):405-11 [PMID: 8597949]
  73. Immunol Rev. 2006 Dec;214:130-42 [PMID: 17100881]
  74. Hum Reprod. 2008 Apr;23(4):972-6 [PMID: 18263639]
  75. J Exp Med. 1992 Mar 1;175(3):709-18 [PMID: 1371301]
  76. Genes Immun. 2005 Dec;6(8):683-90 [PMID: 16121209]
  77. Annu Rev Immunol. 2002;20:217-51 [PMID: 11861603]
  78. J Virol. 2002 Jun;76(12):5925-36 [PMID: 12021325]

MeSH Term

Adolescent
Adult
Aged
CD4-Positive T-Lymphocytes
Disease Progression
Female
Genotype
HIV Infections
HIV-1
HLA-B Antigens
Humans
Killer Cells, Natural
Male
Mexican Americans
Middle Aged
Receptors, KIR3DL1
Receptors, KIR3DS1
Young Adult

Chemicals

HLA-B Antigens
HLA-Bw4 antigen
Receptors, KIR3DL1
Receptors, KIR3DS1

Word Cloud

Created with Highcharts 10.0.0CD4cellHIVTpatientsKIRhumaninfectionMexicanmestizosHLAassociatedimmunodeficiencyviruspopulationscellsresultsimmunefactorsnumbersassessedtimemedicalevaluationfollow-upcountstherapy-experiencedHLA-Bw4Certaingenotypiccombinationskiller-cellimmunoglobulin-likereceptorsleukocyteantigensfavourableoutcomesexposureCaucasoidAfricanHumancharacterizedrapidexhaustionimpairedcellularimmunityearlyphasethoughtnaturalkillerNKrepresentmaineffectorarmhostresponsestudyinvestigateswhetherinitialsubsequentclinicalHLA-Bgenecarrierfrequencydifferencescomparedgroupsstratifiedfirstpointanti-retroviraltherapynaïveadditioninfluencegeneticaveragedhistoricalsubjectedmostlyalsoevaluatedsuggestprotectiveroleKIR3D + Bw4combinationtherapy-naïvereportfurthersunderstandingwaygenesmodulatediseaseprogressionless-studiedspecialfocusnumberbehaviourAssociationKIR3DL1/S1HIV-infected

Similar Articles

Cited By (2)